Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Publications

A systems biology approach to define SARS-CoV-2 correlates of protection.

Brady C. et al, (2025), NPJ Vaccines, 10

Silaproline-bearing nirmatrelvir derivatives are potent inhibitors of the SARS-CoV-2 main protease highlighting the value of silicon-derivatives in structure-activity-relationship studies.

Laczi D. et al, (2025), Eur J Med Chem, 291

Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals.

Mellors J. et al, (2025), Nat Commun, 16

Detection of mpox and other orthopoxviruses using a lateral flow device as a point-of-care diagnostic.

Laidlaw SM. et al, (2025), Microbiol Spectr

Using minor variant genomes and machine learning to study the genome biology of SARS-CoV-2 over time.

Dong X. et al, (2025), Nucleic Acids Res, 53

Host-pathogen interactions of emerging zoonotic viruses: bats, humans and filoviruses.

Hood G. and Carroll M., (2024), Curr Opin Virol

Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials.

Chan XHS. et al, (2024), Lancet Microbe

rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l'essai proches).

Watson CH. et al, (2024), BMC Med, 22

Performance of an envelope glycoprotein-based multiplex immunoassay for Ebola virus antibody detection in a cohort of Ebola virus disease survivors.

Roe MD. et al, (2024), J Virol Methods, 331

Immunogenicity of COVID-19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy.

Lim YJ. et al, (2024), Br J Haematol, 205, 440 - 451

Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.

Goodyear CS. et al, (2024), Lancet Rheumatol, 6, e339 - e351

Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2.

Cornish K. et al, (2024), Open Biol, 14

Serological evidence of zoonotic filovirus exposure among bushmeat hunters in Guinea.

Akoi Boré J. et al, (2024), Nat Commun, 15

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study.

Jackson S. et al, (2024), Lancet Microbe

Obesity Differs from Diabetes Mellitus in Antibody and T Cell Responses Post COVID-19 Recovery.

Ali M. et al, (2024), Clin Exp Immunol

Nipah Virus Therapeutics: A Systematic Review to Support Prioritisation for Clinical Trials

Chan XHS. et al, (2024)

Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.

Mellors J. and Carroll M., (2024), Cell Mol Life Sci, 81

Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model

Wing PAC. et al, (2022)

Quantifying human-animal contact rates in Malaysian Borneo: Influence of agricultural landscapes on contact with potential zoonotic disease reservoirs.

Klim H. et al, (2022), Front Epidemiol, 2

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Load More